Latest news
Climb Bio (NASDAQ:CLYM) Is In A Good Position To Deliver On Growth Plans - simplywall.stsimplywall.st · Sat, 08 Aug 2026 13:38:44 GMTOppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - MoomooMoomoo · Sat, 08 Aug 2026 00:18:39 GMTCLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - BitgetBitget · Fri, 07 Aug 2026 11:54:35 GMTClimb Bio, Inc. Stock 12‑Month Price Target Raised to $21.93, Implies 76% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:12 GMTClimb Bio Releases Q2 2026 Financial Results - AlphaStreetAlphaStreet · Thu, 06 Aug 2026 18:45:04 GMTClimb Bio Reports Q2 2026 Financial Results and Pipeline Updates in Nasdaq 10-Q Filing - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 17:41:02 GMTClimb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:51:01 GMTClimb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock TitanStock Titan · Thu, 06 Aug 2026 11:46:28 GMT